Dear Esteemed Shareholders
As another transformative year unfolds for CytoDyn Inc. (OTC: CYDY), I am excited to share our significant strides toward advancing leronlimab as a leading treatment in oncology. We firmly believe that addressing the substantial unmet medical needs in this area is paramount to enhancing patient outcomes and driving value for our stakeholders. Our confidence in leronlimab is backed by robust preclinical and clinical data, showcasing its potential to redefine treatment approaches in solid tumors. This journey has been marked by consistent validation through recent findings, presenting a compelling narrative of progress. Our various clinical trials emphasize our commitment and urgency in advancing under a structured direction.
Leadership Enhancements
To steer us in this pivotal direction, we have brought on board Robert E. Hoffman as our new Chief Financial Officer. With extensive expertise gained over decades in biotechnology, Robert is set to augment our financial strategies and growth prospects significantly. His insightful approach to capital markets and strategic development will bolster our ability to network and expand CytoDyn’s innovative portfolio. We are thrilled to have his expertise guiding our efforts.
Scientific Developments and Clinical Initiatives
Central to leronlimab's promise is its unique mechanism of action linked to improved survival rates in patients suffering from Metastatic Triple-Negative Breast Cancer (mTNBC). Recent presentations at professional gatherings have unveiled compelling data suggesting that leronlimab may enhance PD-L1 expression, thereby amplifying the effects of immune checkpoint inhibitors (ICIs). The implications of these findings open up new therapeutic avenues, thereby representing a vital market opportunity for our Company. Further insights on this mechanism will be detailed in subsequent updates.
Focus on mTNBC
The potential benefit of leronlimab in mTNBC, classified by notoriously low five-year survival rates, is a focal point for us. We are gearing up to propose a follow-up Phase II proof of concept protocol specifically targeting PD-L1-negative patient groups, who are currently ineligible for ICI therapies. This new treatment phase will combine leronlimab with standard chemotherapy, enhancing prospects for patient response to subsequent treatments. We are keen to share additional details following the FDA’s review of our protocol and accompanying data.
Expanded Access and New Opportunities
Alongside this, we are eager to initiate an Expanded Access Protocol, allowing treatment options for patients who have exhausted standard options. A generous benefactor has shown commitment to fund this compassionate use program, as well as support for an investigator-initiated study in patients with recurrent glioblastoma.
Advancements in Colorectal Cancer
Leronlimab’s applications extend beyond breast cancer; we are actively progressing in the treatment of metastatic Colorectal Cancer (mCRC). Our Phase II study is currently underway across multiple sites, with ongoing tracking of PD-L1 levels among participants. The upcoming DSMB safety review will allow for the introduction of a 700 mg dose in the study, and we have ensured a rollover protocol enables stable patients to continue receiving treatment beyond standard timelines.
Regulatory Updates and Company Directions
Recent positive communications from the Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) regarding their investigations mark a significant milestone for us. This outcome echoes our unwavering dedication to compliance and sets the stage for the productive collaboration we have cultivated with regulatory bodies, including the FDA. Our newly established oncology advisory board is focused on expediting responsible pathways for our research endeavors, ensuring we can push forward effectively in this critical field.
A Commitment to Stakeholders
Your continued support has been invaluable over the years. We commit to transparency and open dialogue with all shareholders. We appreciate your patience and continuous feedback as it guides us toward success. Your inquiries are always welcome via our investor relations email, and effective communication remains a priority as we engage with key opinion leaders and regulators in the coming months.
A Personal Reflection
As we strive to improve the lives of our patients, I am always reminded of the real people impacted by our work. Recently, I had the uplifting experience of dining with a mTNBC survivor who had reduced treatment options yet now enjoys precious moments with her family. The hope reflected in our conversations fueled my passion for our mission here at CytoDyn as we pursue advancements in treatment for patients across various oncological challenges.
Frequently Asked Questions
What is CytoDyn Inc.'s main focus in oncology?
CytoDyn Inc. primarily focuses on advancing leronlimab as a treatment for various solid tumors, particularly targeting unmet medical needs in oncology.
Who is the new CFO of CytoDyn and what expertise does he bring?
Robert E. Hoffman is the new CFO, bringing extensive experience in financial management and executive leadership within the biotech sector.
What are the implications of leronlimab’s mechanism of action?
Leronlimab's unique mechanism can enhance PD-L1 expression and synergize with immune checkpoint inhibitors, potentially changing treatment landscapes in solid tumors.
How is CytoDyn expanding access to treatment?
The Company is implementing an Expanded Access Protocol for mTNBC patients to receive treatment with leronlimab, facilitating access to those in need.
What is the status of regulatory matters for CytoDyn?
CytoDyn has received confirmation that investigations by the SEC and DOJ have concluded positively, allowing the Company to concentrate on its core objectives.
